Joseph A. O’Donoghue

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Neeta Pandit‐Taskar, Michael A. Postow, Matthew D. Hellmann et al. · Journal of Nuclear Medicine · 2019 · 262 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Neeta Pandit‐Taskar, Joseph A. O’Donoghue, Jeremy C. Durack et al. · Clinical Cancer Research · 2015 · 204 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study

Shelley Potter, Elizabeth J. Conroy, Ramsey I Cutress et al. · The Lancet Oncology · 2019 · 202 citations · Full text

Medicine, Plastic Surgery, Surgery +16

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models

Joseph A. O’Donoghue, Pat Zanzonico, Andrei Pugachev et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 183 citations

Medicine, Nuclear Medicine, Oncology +17

Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

Jorge A. Carrasquillo, Joseph A. O’Donoghue, Neeta Pandit‐Taskar et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 182 citations

Pharmacy, Pharmacokinetics, Pharmacology +14